Australia - engelsk - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - mesna, quantity: 100 mg/ml - injection, solution - excipient ingredients: disodium edetate; water for injections; nitrogen; sodium hydroxide - for the reduction and prevention of urinary tract toxicity (haemorrhagic cystitis) of oxazaphosphorines (see adverse effects sections of the cyclophosphamide and ifosfamide product information).

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - mesna, quantity: 100 mg/ml - injection, solution - excipient ingredients: sodium hydroxide; nitrogen; water for injections; disodium edetate - for the reduction and prevention of urinary tract toxicity (haemorrhagic cystitis) of oxazaphosphorines (see adverse effects sections of the cyclophosphamide and ifosfamide product information).

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - mesna, quantity: 100 mg/ml - injection, solution - excipient ingredients: water for injections; nitrogen; sodium hydroxide; disodium edetate; benzyl alcohol - for the reduction and prevention of urinary tract toxicity (haemorrhagic cystitis) of oxazaphosphorines (see adverse effects sections of the cyclophosphamide and ifosfamide product information).

Spania - spansk - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

altan pharmaceuticals sa - mesna - soluciÓn inyectable y para perfusiÓn - 400 mg - mesna 100 mg - mesna

Spania - spansk - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

altan pharmaceuticals sa - mesna - soluciÓn para instilaciÓn endotraqueopulmonar - 600 mg - mesna 200 mg - mesna

USA - engelsk - NLM (National Library of Medicine)

gland pharma limited - mesna (unii: nr7o1405q9) (2-mercaptoethanesulfonic acid - unii:vhd28s0h7f) - mesna 100 mg in 1 ml - mesna injection is indicated as a prophylactic agent in reducing the incidence of ifosfamide-induced hemorrhagic cystitis. limitation of use : mesna injection is not indicated to reduce the risk of hematuria due to other pathological conditions such as thrombocytopenia. mesna injection is contraindicated in patients known to be hypersensitive to mesna or to any of the excipients [see warnings and precautions (5.1)]. risk summary mesna injection is used in combination with ifosfamide or other cytotoxic agents. ifosfamide can cause fetal harm when administered to a pregnant woman. refer to the ifosfamide prescribing information for more information on use during pregnancy. mesna injection contains the preservative benzyl alcohol. because benzyl alcohol is rapidly metabolized by a pregnant woman, benzyl alcohol exposure in the fetus is unlikely [see warnings and precautions (5.3) and use in specific populations (8.4)]. the estimated background risk of major birth defects and miscarriage fo

Brasil - portugisisk - ANVISA (Agência Nacional de Vigilância Sanitária)

eurofarma laboratÓrios s.a. - mesna - produtos para vias urinarias

Frankrike - fransk - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

eg labo - laboratoires eurogenerics - mesna 100 mg - solution - 100 mg - pour 1 ml de solution > mesna 100 mg - médicaments detoxifiants dans un traitement cytostatique - classe pharmacothérapeutique - code atc : v03af01.ce médicament appartient à la classe des médicaments détoxifiants utilisés lors d’un traitement cytostatique.mesna eg est indiqué dans la prévention de la toxicité urinaire des oxazaphosphorines (cyclophosphamide, ifosfamide, trofosfamide).

Malta - engelsk - Medicines Authority

baxter healthcare limited - mesna - solution for injection - mesna 100 mg/ml - all other therapeutic products

USA - engelsk - NLM (National Library of Medicine)

baxter healthcare corporation - mesna (unii: nr7o1405q9) (2-mercaptoethanesulfonic acid - unii:vhd28s0h7f) - mesna 100 mg in 1 ml - mesna is indicated as a prophylactic agent in reducing the incidence of ifosfamide-induced hemorrhagic cystitis. limitation of use: mesna is not indicated to reduce the risk of hematuria due to other pathological conditions such as thrombocytopenia. mesna is contraindicated in patients known to be hypersensitive to mesna or to any of the excipients [see warnings and precautions (5.1)] . risk summary mesna is used in combination with ifosfamide or other cytotoxic agents. ifosfamide can cause fetal harm when administered to a pregnant woman. refer to the ifosfamide prescribing information for more information on use during pregnancy. mesna injection contains the preservative benzyl alcohol. because benzyl alcohol is rapidly metabolized by a pregnant woman, benzyl alcohol exposure in the fetus is unlikely [see warnings and precautions (5.3) and use in specific populations (8.4)]. the estimated background risk of major birth defects and miscarriage for the indicated populations are unknown. all pregnancies